The global CRISPR/Cas9
licensing leader

Based on the Nobel Prize winning invention of
Emmanuelle Charpentier & Jennifer Doudna,
CRISPR/Cas9 has transformed gene editing.

ERS licenses worldwide access to the essential
CRISPR/Cas9 patent portfolio

"This is transformative technology that allows the recoding of life and editing"

Emmanuelle Charpentier
ERS co-founder, patent co-owner
& 2020 Nobel prize winner

The essential intellectual property for the practice of CRISPR/Cas9

Consisting of over 85 issued patents in over 80 countries, our portfolio represents the most foundational collection of CRISPR/Cas9 patents worldwide.